DBV Technologies (NASDAQ:DBVT) Sees Unusually-High Trading Volume – Should You Buy?

Shares of DBV Technologies S.A. (NASDAQ:DBVT) saw an uptick in trading volume on Tuesday . Approximately 341,260 shares changed hands during trading, an increase of 15% from the previous session’s volume of 295,852 shares.The stock last traded at $14.06 and had previously closed at $14.57.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on DBVT shares. Citizens Jmp lifted their price objective on DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research report on Tuesday, June 30th. Weiss Ratings downgraded DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. Wall Street Zen cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Finally, Guggenheim reiterated a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a research note on Monday, May 4th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Stock Down 3.8%

The company has a 50 day moving average price of $17.02 and a 200-day moving average price of $19.45. The company has a market cap of $829.56 million, a price-to-earnings ratio of -3.99 and a beta of -0.95.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Thursday, July 16th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.48). DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%.The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $0.90 million. On average, analysts forecast that DBV Technologies S.A. will post -0.38 EPS for the current fiscal year.

Institutional Trading of DBV Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. UBS Group AG lifted its position in shares of DBV Technologies by 165,347.3% in the 4th quarter. UBS Group AG now owns 244,862 shares of the company’s stock worth $4,694,000 after purchasing an additional 244,714 shares during the period. Diversify Wealth Management LLC acquired a new stake in shares of DBV Technologies during the first quarter worth $1,293,000. Dorsey Wright & Associates bought a new position in DBV Technologies during the first quarter worth $2,142,000. Polymer Capital Management HK LTD acquired a new position in shares of DBV Technologies in the 4th quarter valued at about $1,236,000. Finally, AdvisorShares Investments LLC acquired a new position in shares of DBV Technologies during the 1st quarter valued at $1,052,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.